Want to see AU:PCK full AI Analyst Report?
Top Page
PainChek Ltd
(Sydney:PCK)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.11
▼(-63.45% Downside)
Action:Reiterated
Date:08/29/26
The score is held down primarily by weak financial performance—deep losses, heavy and worsening cash burn, negative equity, and added debt—despite strong revenue growth and improved gross margin. Technicals also remain bearish with the price below major moving averages and a negative MACD. Valuation contributes little support due to negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Revenue Growth
Rapid revenue expansion indicates increasing adoption of PainChek’s platform and a growing commercial footprint. If this trajectory continues, greater scale could improve operating leverage, support investment in product development, and strengthen the company’s position in digital pain assessment.
Negative Factors
Deep Operating Losses
The company has not yet demonstrated a viable path to profitability despite strong revenue growth and improved gross margins. Persistent operating losses indicate that the current revenue base remains insufficient to cover the cost structure, limiting the durability of earnings and increasing funding needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Rapid revenue expansion indicates increasing adoption of PainChek’s platform and a growing commercial footprint. If this trajectory continues, greater scale could improve operating leverage, support investment in product development, and strengthen the company’s position in digital pain assessment.
Read all positive factors
PainChek Ltd (PCK) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$22.99M
Dividend YieldN/A
Average Volume (3M)143.58K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth11.45%
EPS Growth0.69%
CountryAU
Employees25
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.04
Shares Outstanding209,007,310
10 Day Avg. Volume232,168
30 Day Avg. Volume143,582
Financial Highlights & Ratios
PEG Ratio1.77
Price to Book (P/B)-15.11
Price to Sales (P/S)5.78
P/FCF Ratio-2.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PainChek Ltd Business Overview & Revenue Model
Company Description
PainChek Limited specializes in the creation and commercialization of mobile medical applications designed for individual pain assessment. Their core product, PainChek, employs smartphone and tablet cameras to record video, which is then analyzed ...
How the Company Makes Money
PainChek makes money primarily by licensing and selling access to its PainChek software platform to organisations that need to assess and document pain, particularly in aged care and clinical settings. Revenue is typically generated through recurr...
PainChek Ltd Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
22
Negative
Cash Flow
18
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.74M | 3.36M | 2.67M | 1.95M | 978.57K |
| Gross Profit | 2.64M | 997.74K | 726.66K | 712.51K | -258.82K |
| EBITDA | -9.92M | -7.65M | -9.49M | -8.61M | -6.80M |
| Net Income | -8.94M | -7.67M | -8.31M | -7.57M | -5.72M |
Balance Sheet | |||||
| Total Assets | 7.63M | 2.15M | 4.18M | 2.80M | 6.65M |
| Cash, Cash Equivalents and Short-Term Investments | 5.99M | 1.62M | 3.56M | 2.51M | 6.14M |
| Total Debt | 4.25M | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 9.06M | 3.26M | 2.89M | 2.13M | 1.83M |
| Stockholders Equity | -1.43M | -1.11M | 1.29M | 668.13K | 4.82M |
Cash Flow | |||||
| Free Cash Flow | -9.25M | -6.77M | -7.16M | -6.34M | -7.02M |
| Operating Cash Flow | -9.24M | -6.75M | -7.13M | -6.32M | -7.00M |
| Investing Cash Flow | -14.93K | -12.17K | -34.25K | -12.44K | -21.96K |
| Financing Cash Flow | 13.64M | 4.82M | 8.21M | 2.70M | 1.75M |
PainChek Ltd Technical Analysis
Positive
0.29
Price Trends
0.10
Positive
0.12
Negative
0.18
Negative
Market Momentum
>-0.01
Negative
61.81
Neutral
34.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PCK, the sentiment is Positive. The current price of 0.29 is above the 20-day moving average (MA) of 0.10, above the 50-day MA of 0.10, and above the 200-day MA of 0.18, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 61.81 is Neutral, neither overbought nor oversold. The STOCH value of 34.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:PCK.
PainChek Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | AU$530.83M | 32.03 | 21.61% | 1.94% | 6.95% | 10.77% | |
61 Neutral | AU$141.73M | 61.76 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$163.64M | -9.45 | -203.69% | ― | -1.53% | 28.29% | |
50 Neutral | AU$18.60M | ― | -578.72% | ― | 113.42% | 29.17% | |
49 Neutral | AU$35.44M | -1.91 | -58.13% | ― | 2.08% | -195.31% | |
43 Neutral | AU$22.99M | -2.53 | -1688.04% | ― | 11.45% | 0.69% |
* Healthcare Sector Average
AU:PCK
PainChek Ltd
0.11
-0.33
-75.00%
AU:CGS
Cogstate Ltd
3.09
1.38
81.02%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.20
-0.04
-17.02%
AU:BMT
Beamtree Holdings Ltd
0.12
-0.11
-47.83%
AU:ALC
Alcidion Group Limited
0.11
0.02
16.67%
AU:ICR
InteliCare Holdings Limited
0.03
<0.01
52.94%
PainChek Ltd Corporate Events
PainChek to Brief Investors on Global AI Pain Platform Expansion and U.S. Growth Strategy
Sep 3, 2026
PainChek Ltd, a healthcare technology company specialising in AI-driven pain assessment tools, is expanding its presence across key international healthcare markets following regulatory clearances in regions including Australia, Europe, and the Un...
PainChek posts higher revenue but deeper loss as going-concern flagged
Aug 28, 2026
PainChek Ltd reported total revenue of $4.9 million for the year ended 30 June 2026, a modest increase of 2% on the prior year, supported by higher core revenue and interest income but offset by a reduction in grants. The company’s net loss ...
PainChek flags growth momentum and U.S. push ahead of investor webinar
Aug 7, 2026
PainChek Ltd, a medical device and AI-enabled pain assessment specialist, is expanding its global footprint with regulatory clearances across multiple regions including recent FDA De Novo clearance in the United States, and has built a substantial...
PainChek Updates Performance Rights Following Share Consolidation
Aug 5, 2026
PainChek Ltd has updated its previously reported figures for unquoted performance rights following a recent share consolidation, revising the allocations for several key individuals, including J. Murray, R. Harricks, C. Payne and A. Davey. The tot...
PainChek Updates Director Adam Davey’s Equity and Performance Rights Holdings
Aug 5, 2026
PainChek Limited has disclosed a change in director Adam Davey’s interests in the company’s securities, reflecting an updated mix of fully paid ordinary shares and newly issued performance rights. The adjustments include both direct an...
PainChek turns market access into revenue as U.S. rollout begins
Jul 29, 2026
PainChek reported steady operational growth in the June quarter, with implemented licences rising 5.9% to 90,198 and implemented annual recurring revenue reaching $4.46 million across nearly 2,000 active customer sites. Clinical usage continued to...
PainChek boosts cash reserves with $1.1m R&D tax refund to drive global AI pain platform
Jul 21, 2026
PainChek Ltd, an ASX-listed health technology company, develops AI-enabled pain assessment and monitoring applications that serve people who cannot reliably self-report pain, those who can, and those whose ability fluctuates. Its flagship PainChek...
PainChek Discloses Final Director Interest Following Board Departure
Jul 8, 2026
PainChek Limited has disclosed that Philip Daffas ceased to be a director on 6 July 2026, lodging a final director’s interest notice with the ASX. The filing details his remaining holdings in fully paid ordinary shares and performance rights...
PainChek Reshapes Leadership to Drive Post-FDA U.S. Growth
Jul 6, 2026
PainChek Ltd has announced an immediate change in leadership, with long-serving CEO and Managing Director Philip Daffas stepping down as part of a planned transition tied to the company’s Financial Year 2027 strategy following FDA De Novo cl...
PainChek trims potential dilution as unexercised options lapse
Jul 3, 2026
PainChek Ltd has announced the cessation of several series of employee or conditional options, totalling more than 570,000 securities, following either the lapse of conditions attached to those rights or the expiry of the options without exercise....
PainChek issues over 3 million unquoted performance rights under employee incentive plan
Jun 26, 2026
PainChek Ltd has issued 3,026,634 unquoted performance rights under its employee incentive scheme, with the securities recorded as being issued on 19 June 2026. The move signals continued use of equity-based remuneration to align staff incentives ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.